
AMGEN/X
Jun 25, 2025, 16:24
Results From Amgen’s Phase 2 Obesity Study of Monthly Maritide Presented at the American Diabetes Association 85th Scientific Sessions
Amgen shared a post on X:
“Results from Amgen’s Phase 2 obesity study being presented during an expert-led symposium at the American Diabetes Association 85th Scientific Sessions.
The data evaluated MariTide in people living with obesity, with and without Type 2 diabetes.
Proceed to the video attached to the post.
More posts featuring AMGEN.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 6, 2025, 06:26
Aug 6, 2025, 05:59
Aug 6, 2025, 05:45
Aug 6, 2025, 05:24
Aug 6, 2025, 04:54